XML 81 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business combinations (Tables)
 12 Months Ended
Jun. 30, 2018
Text block1 [abstract]  
Summary of details of acquisition

Details of the acquisition are as follows:

 

     Fair
value
A$’000		  

Intellectual property

      16,408  

Deferred tax liability

      (4,512 ) 
  

 

 

  

Net assets acquired

      11,896  

Goodwill

      —    
  

 

 

  

Acquisition-date fair value of the total consideration transferred

      11,896  
  

 

 

  

Representing:

   

Cash paid or payable to vendor

      7,097  

Kazia Therapeutics Limited shares issued to vendor

      1,544  

Contingent consideration

      3,255  
  

 

 

  
     11,896  
  

 

 

  

 

    

Consolidated
2017

A$’000

  

Cash used to acquire business, net of cash acquired:

   

Acquisition-date fair value of the total consideration transferred

      16,408  

Less: contingent consideration

      (3,255 ) 

Less: shares issued by company as part of consideration

      (1,544 ) 

Less: Deferred Tax Liability

      (4,512 ) 
  

 

 

  

Net cash used

      7,097  
  

 

 

  
Summary of range of outcomes of contingent consideration

The range of outcomes of contingent consideration are summarised below.

 

Milestone    Contingent consideration-High    Contingent consideration-Low
     A$’000    A$’000

Milestone 1

    1,250    1,250

Milestone 2

    1,250    1,250

Milestone 3

    3,705    3,000

Milestone 4

    4,199    3,400

Milestone 5

    1,394    1,394
  

 

   

 

Total

    11,798    10,294